Second-generation antipsychotics: cost-effectiveness, policy options, and political decision making.

Clinical trial-based cost-effectiveness analyses of antipsychotic use.

OBJECTIVE Second-generation antipsychotics make up one of the fastest growing segments of the rapidly growing pharmaceutical sector. Given limited health care resources, assessment of the value for the cost of second-generation antipsychotics relative to first-generation antipsychotics is critical for resource-allocation decisions. METHOD With a MEDLINE search, the authors identified eight st...

Use of Cost-Effectiveness Data in Priority Setting Decisions: Experiences from the National Guidelines for Heart Diseases in Sweden

Background The inclusion of cost-effectiveness data, as a basis for priority setting rankings, is a distinguishing feature in the formulation of the Swedish national guidelines. Guidelines are generated with the direct intent to influence health policy and support decisions about the efficient allocation of scarce healthcare resources. Certain medical conditions may be given higher priority ran...

Including Both Costs and Effects – The Challenge of Using Cost-Effectiveness Data in National-Level Policy-Making: A Response to Recent Commentaries

New generation vs. first generation antipsychotics debate: pragmatic clinical trials and practice-based evidence.

There has been significant confusion about the relative advantage of new generation antipsychotics over first generation antipsychotics as well as of clinical trials performed to evaluate their efficacy vs. those designed to evaluate their effectiveness. Pragmatic or effectiveness clinical trials like CATIE and CUtLASS sponsored by governments have challenged the current worldview of the greate...

Cost-effectiveness analysis of olanzapine and risperidone in Norway.

BACKGROUND Antipsychotic medications are the mainstay for schizophrenia treatment, and olanzapine and risperidone are popular choices among atypical antipsychotics in Norway. Our aim was to develop a decision analytic model to evaluate the cost-effectiveness of antipsychotics in a Norwegian setting. METHODS The Positive and Negative Symptom Scale (PANSS) score was used to measure effectivenes...